KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. While EKTERLY's early market adoption and strong focus on high-burden patients are positive, the lack of specific financial guidance and uncertainty around revenue projections and pricing in Germany introduce caution. The Q&A reveals concerns about demand fluctuations and management's reluctance to provide clear revenue guidance, which tempers overall optimism. The neutral sentiment reflects these balanced positive and negative factors, with no strong catalysts or deterrents to drive significant stock price movement in the short term.
Key Financial Performance
Sales of EKTERLY $13.7 million for the launch period through September 30, which includes $1.4 million recorded in July. The sales were driven by specialty pharmacy partners stocking additional locations and building inventory to support growing patient demand.
Operating Expenses $59.7 million for the period, consisting of approximately $12 million in R&D expenses and approximately $46.5 million in SG&A expenses. SG&A expenses are expected to remain consistent as investments in EKTERLY's global launch continue.
Gross to Net Came in towards the low end of the expected range this quarter, driven largely by lower co-pay utilization typical for this time of year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EKTERLY Launch: EKTERLY has been launched in the U.S. with steady adoption and strong demand. It is being used to treat a significant number of HAE attacks and is meeting patient expectations for efficacy and safety. The German launch has also begun, with initial uptake validating interest outside the U.S. Approvals have been secured in Australia, U.K., EU, and Switzerland.
KONFIDENT-KID Trial: Interim results show sebetralstat enables early, effective, and safe treatment of HAE attacks in children aged 2 to 11. The trial has fully recruited 36 children almost a year ahead of schedule, highlighting unmet needs. The median time to symptom relief was 1.5 hours, with no treatment-related adverse events.
KONFIDENT-S Trial: Data from over 2,700 attacks treated with EKTERLY shows reduced use of second doses and injectables over time, indicating growing patient confidence. High satisfaction rates were reported among patients switching from injectable therapies to sebetralstat.
Global Expansion: EKTERLY has been launched in Germany and is preparing for launches in the U.K. and Japan in 2026. Pricing and reimbursement discussions are ongoing in the U.K., and approval is being pursued in Japan with a partner.
Financial Performance: EKTERLY generated $13.7 million in sales during its initial 3-month launch period. Operating expenses were $59.7 million, with $12 million in R&D and $46.5 million in SG&A. The company is fully financed through profitability.
New Hires: Bilal Arif has been hired as Chief Operating Officer and Linea Aspesi as Chief People Officer, both bringing decades of experience to support the company's growth.
Strategic Positioning: The company aims to establish EKTERLY as the foundational therapy for HAE, displacing injectable options. It is focused on scaling in the U.S., expanding global access, and reinforcing confidence in EKTERLY's role across the treatment landscape.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Market Access Challenges: The company is still in the process of advancing pricing and reimbursement discussions in the U.K. and Japan, which could delay market access and revenue generation in these regions. Additionally, some U.S. payers require a step through icatibant, which could slow adoption.
Supply Chain and Inventory Risks: Specialty pharmacy partners are building inventory to meet growing demand, but any disruptions in the supply chain or inventory management could impact the availability of EKTERLY.
High Initial Costs and SG&A Expenses: The company reported $46.5 million in SG&A expenses for the quarter, with expectations for these costs to remain consistent as they invest in EKTERLY's global launch. This could strain financial resources if revenue growth does not meet expectations.
Dependence on High-Burden Patients: Early adoption of EKTERLY is primarily among high-burden patients. If the broader HAE population does not adopt the therapy at similar rates, it could limit long-term growth.
Competitive Pressures: The company faces competition from existing injectable on-demand therapies and must continue to demonstrate EKTERLY's advantages to maintain and grow market share.
Economic and Payer Dynamics: Economic uncertainties and payer policies could impact the affordability and accessibility of EKTERLY, potentially limiting its adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Global Expansion of EKTERLY: KalVista is actively working on expanding EKTERLY's reach globally. The German launch has begun, and approval has been received in Australia, U.K., EU, and Switzerland. Pricing and reimbursement discussions are underway in the U.K. for a first-half 2026 launch, and a launch in Japan is expected in Q1 2026 with Kaken Pharmaceutical.
Pediatric NDA Submission: KalVista plans to submit a New Drug Application (NDA) for pediatric use of EKTERLY in Q3 2026, based on the KONFIDENT-KID trial results.
Market Access and Payer Coverage: Efforts are ongoing to formalize EKTERLY's access with payers, aiming for broader coverage in early 2026. Medical exceptions have been approved by all PBMs and large payers for both commercial and Medicare cases.
Revenue Growth and Financial Outlook: EKTERLY sales reached $13.7 million in the initial 3-month launch period. The company is fully financed through profitability, with SG&A expenses expected to remain consistent as global launch investments continue.
Clinical Data and Patient Satisfaction: KalVista continues to generate clinical data to support EKTERLY's efficacy and safety. High patient satisfaction rates and reduced reliance on injectable therapies are expected to drive long-term adoption.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What trends are observed for patients switching to EKTERLY, particularly high-burden patients?
A:Roughly half of the patients switching to EKTERLY self-report an attack rate of 2 or more attacks per month, indicating a high treatment burden. These patients refill at higher rates and in larger quantities. Over time, as EKTERLY's reach broadens, refill rates and quantities per refill are expected to decline.
Q:What is the proportion of paid versus free drug for the 937 new starts?
A:The paid rate continues to grow week-to-week, and medical exceptions have been successfully used. EKTERLY policies are providing clarity for patient access, and all start forms reflect prescriptions for patients switching to EKTERLY.
Q:What are the refill rates and average doses for high-burden patients?
A:High-burden patients refill more frequently, about once a month or more, with multiple cartons per refill. This is higher than the average refill rate of once every 3-4 months seen with other treatments like FIRAZYR or icatibant. Over time, refill rates and volumes are expected to normalize.
Q:Are there quantity limits for EKTERLY, and how do they compare to other treatments?
A:Quantity limits for EKTERLY are consistent with other branded on-demand treatments and have not impeded patient access. There are means to overcome quantity limits if needed.
Q:What are the expectations for demand and patient bolus dynamics for the remainder of the year and next year?
A:Demand may slow during the holiday season due to reduced physician availability. Over time, the rate of patient start forms (PSFs) is expected to slow as the patient population deepens. The company is cautious about providing specific projections for 2026.
Q:Is there any stockpiling behavior observed among patients using EKTERLY?
A:It is unclear if patients are stockpiling EKTERLY. High refill rates may reflect high attack rates or stockpiling for convenience. Treatment guidelines encourage patients to keep enough product on hand for 2-3 attacks.
Q:What is the expected trajectory for PSF growth and ex-U.S. launches?
A:PSF growth has been consistent but may slow during the holiday season and over time as the patient population deepens. The German launch is underway, with pricing not yet disclosed. The U.K. launch is planned for the first half of 2026, with other European countries following later in the year.
Q:What are the expectations for EKTERLY adoption among low-burden patients?
A:While high-burden patients are the initial focus, the company expects oral therapies like EKTERLY to eventually displace injectables across all patient groups. Satisfaction rates are high among both high- and low-burden patients.
Q:What is the gross-to-net range for EKTERLY?
A:The gross-to-net range for EKTERLY is expected to be in the upper teens to low 20s.
Q:What is the role of high-burden patients in EKTERLY's initial adoption?
A:High-burden patients are the most informed and actively seek new treatments. Physicians also prioritize these patients due to their high need, which helps validate EKTERLY's clinical trial profile in real-world settings.
Q:What is the status of inventory and specialty pharmacy performance?
A:Specialty pharmacies are building inventory in anticipation of demand. Inventory levels are not yet at steady state and are expected to continue growing.
Q:How are insurance negotiations progressing, and what is the expected timeline for payer policies?
A:Insurance negotiations are progressing as expected, with favorable policies being established by regional and national payers. Larger payer and PBM discussions are expected to conclude by early 2026.
Q:What is the expected revenue trajectory for EKTERLY in the near term?
A:Revenue may be bumpy in the early quarters as refill rates stabilize. The holiday period and the on-demand nature of the therapy add uncertainty to short-term revenue projections.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the expected revenue trajectory for EKTERLY, citing the on-demand nature of the therapy and the holiday season as factors contributing to uncertainty. They also did not disclose the price agreed upon for the German launch, stating that it is still under negotiation.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACAAI
EKTERLY attack
Financial Update
HAE child
HAE community
HCPs
KID trial
KONFIDENT KID
PBMs payer
Pharmaceuticals Financial
Update Results
adolescent
age
attack child
attack patient
attack result
attack sebetralstat
child attack
child caregiver
depth
disease burden
dose
end utilization
enthusiasm
hour
level satisfaction
minute
momentum
note
participant
patient attack
patient month
profitability
satisfaction score
segment
trial HAE
trial attack
trial sebetralstat
update KONFIDENT
volume
world utilization
KALV Transcript
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
Neutral3-25
KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-24
KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call summary presents a mixed picture. While EKTERLY's early market adoption and strong focus on high-burden patients are positive, the lack of specific financial guidance and uncertainty around revenue projections and pricing in Germany introduce caution. The Q&A reveals concerns about demand fluctuations and management's reluctance to provide clear revenue guidance, which tempers overall optimism. The neutral sentiment reflects these balanced positive and negative factors, with no strong catalysts or deterrents to drive significant stock price movement in the short term.
KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript
Positive9-11
The earnings call summary indicates positive sentiment with strong product development and business updates, including EKTERLY's successful launch and positive feedback on side effects. The Q&A section highlights minimal adverse events and growing patient adoption, which are positive indicators. Despite some unclear management responses, the overall sentiment leans positive due to optimistic guidance and market growth projections.
KALV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
